Anti-phospholipase A2 Receptor Antibodies Directly Induced Podocyte Damage

Overview

Journal Ren Fail

Publisher Informa Healthcare

Date 2022 Mar 25

PMID 35333675

Authors

Yanfen Li

Juntao Yu

Miao Wang

Zhao Cui

Ming-Hui Zhao

Affiliations

Soon will be listed here.

Abstract

Background: The pathogenesis of primary membranous nephropathy (MN) involves the antibodies against antigens on the cell surface of podocytes, with the majority of M-type phospholipase A2 receptor (PLA2R), and a profound podocyte dysfunction. The effects of anti-PLA2R antibodies directly to the podocytes remain unclear.

Methods: Anti-PLA2R antibodies from patients with PLA2R-associated MN were affinity-purified using a column coupled with recombinant human PLA2R protein. Their effects on conditionally immortalized human podocytes were assessed by apoptosis assays, cellular calcium detection, wound healing assay, and immunofluorescent staining. Proteomics analysis was performed by LC-MS/MS and on PANTHER database.

Results: The stimulation by anti-PLA2R antibodies could induce early-stage apoptosis of podocytes (MFI of Annexin = 104.3 ± 19.2 vs. 36.7 ± 7.6, = 0.004). The increase of calcium concentration in podocytes (MFI = 3309.3 ± 363.6 vs. 1776.3 ± 212.7, = 0.015) might attribute to the endoplasmic reticulum calcium efflux. The expression of calcium/calmodulin-dependent protein kinase IV (CaMK4) was also increased (MFI = 134.4 ± 9.8 vs. 105.3 ± 10.1, = 0.011). Proteomics results suggested that anti-PLA2R antibody treatment led to damage on cellular structure, and produced functional disorders on protein binding, actin filament binding, and microtubule motor activity. The staining of F-actin on foot process was reduced (MFI = 27.3 ± 2.8 vs. 47.5 ± 1.0, = 0.001) and the motility and adherence capacity of podocytes were reduced (number of migrated cells = 44.7 ± 3.1 vs. 53.3 ± 4.9, = 0.001) after incubation with anti-PLA2R antibodies.

Conclusion: These data indicate that anti-PLA2R antibodies may directly induce podocyte damage independent of the complement system, which expands the mechanism of anti-PLA2R antibodies on MN.

Citing Articles

Role of PLA2R domain antibodies and epitope spreading in risk stratification and prediction of proteinuria remission in primary membranous nephropathy.

Zhang X, Yang F, Fan Y, Xue J, Liu B, Zhang Z Sci Rep. 2025; 15(1):6868.

PMID: 40011527 PMC: 11865275. DOI: 10.1038/s41598-025-91366-5.

Analysis of survival among biopsy-determined categories of kidney disease in dogs.

Schultz D, Rivera C, Jeffery N, Cianciolo R, Hokamp J, Labato M J Vet Intern Med. 2025; 39(2):e17301.

PMID: 39925194 PMC: 11808253. DOI: 10.1111/jvim.17301.

The Prevalence, Characteristics, and Putative Mechanisms of Dual Antigen-Positive Membranous Nephropathy: The Underestimated Condition.

Uchida T, Oda T Int J Mol Sci. 2024; 25(11).

PMID: 38892120 PMC: 11172907. DOI: 10.3390/ijms25115931.

Clinicopathological and prognostic characteristics of idiopathic membranous nephropathy with dual antigen positivity.

Yang L, Wang G, Ye N, Xu X, Cheng W, Sun L Front Immunol. 2024; 14:1297107.

PMID: 38250076 PMC: 10796489. DOI: 10.3389/fimmu.2023.1297107.

Containing anti-PLA2R IgG antibody induces podocyte injury in idiopathic membranous nephropathy.

Zhang Y, Chen P, Wang B, Tang X, Wei Y, Cao W Ren Fail. 2023; 45(2):2271986.

PMID: 37905942 PMC: 11001355. DOI: 10.1080/0886022X.2023.2271986.

References

Lemrow S, Anderson K, Joseph J, Ribar T, Noeldner P, Means A . Catalytic activity is required for calcium/calmodulin-dependent protein kinase IV to enter the nucleus. J Biol Chem. 2004; 279(12):11664-71. DOI: 10.1074/jbc.M312613200. View

Griveau A, Devailly G, Eberst L, Navaratnam N, Le Calve B, Ferrand M . The PLA2R1-JAK2 pathway upregulates ERRα and its mitochondrial program to exert tumor-suppressive action. Oncogene. 2016; 35(38):5033-42. DOI: 10.1038/onc.2016.43. View

Ichinose K, Ushigusa T, Nishino A, Nakashima Y, Suzuki T, Horai Y . Lupus Nephritis IgG Induction of Calcium/Calmodulin-Dependent Protein Kinase IV Expression in Podocytes and Alteration of Their Function. Arthritis Rheumatol. 2015; 68(4):944-52. PMC: 6103450. DOI: 10.1002/art.39499. View

Liu L, Done S, Khoshnoodi J, Bertorello A, WARTIOVAARA J, Berggren P . Defective nephrin trafficking caused by missense mutations in the NPHS1 gene: insight into the mechanisms of congenital nephrotic syndrome. Hum Mol Genet. 2001; 10(23):2637-44. DOI: 10.1093/hmg/10.23.2637. View

Bernard D, Vindrieux D . PLA2R1: expression and function in cancer. Biochim Biophys Acta. 2014; 1846(1):40-4. DOI: 10.1016/j.bbcan.2014.03.003. View

Sukocheva O, Menschikowski M, Hagelgans A, Yarla N, Siegert G, Reddanna P . Current insights into functions of phospholipase A2 receptor in normal and cancer cells: More questions than answers. Semin Cancer Biol. 2017; 56:116-127. DOI: 10.1016/j.semcancer.2017.11.002. View

Huber T, Hartleben B, Winkelmann K, Schneider L, Becker J, Leitges M . Loss of podocyte aPKClambda/iota causes polarity defects and nephrotic syndrome. J Am Soc Nephrol. 2009; 20(4):798-806. PMC: 2663834. DOI: 10.1681/ASN.2008080871. View

Augert A, Vindrieux D, Girard C, Le Calve B, Gras B, Ferrand M . PLA2R1 kills cancer cells by inducing mitochondrial stress. Free Radic Biol Med. 2013; 65:969-977. DOI: 10.1016/j.freeradbiomed.2013.08.177. View

Hoxha E, Harendza S, Pinnschmidt H, Panzer U, Stahl R . M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy. Clin J Am Soc Nephrol. 2014; 9(11):1883-90. PMC: 4220763. DOI: 10.2215/CJN.03850414. View

10.

Shankland S . The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int. 2006; 69(12):2131-47. DOI: 10.1038/sj.ki.5000410. View

11.

Vindrieux D, Augert A, Girard C, Gitenay D, Lallet-Daher H, Wiel C . PLA2R1 mediates tumor suppression by activating JAK2. Cancer Res. 2013; 73(20):6334-45. DOI: 10.1158/0008-5472.CAN-13-0318. View

12.

Francis J, Beck Jr L, Salant D . Membranous Nephropathy: A Journey From Bench to Bedside. Am J Kidney Dis. 2016; 68(1):138-47. PMC: 4921260. DOI: 10.1053/j.ajkd.2016.01.030. View

13.

Beck Jr L, Bonegio R, Lambeau G, Beck D, Powell D, Cummins T . M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009; 361(1):11-21. PMC: 2762083. DOI: 10.1056/NEJMoa0810457. View

14.

Hoxha E, Thiele I, Zahner G, Panzer U, Harendza S, Stahl R . Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. J Am Soc Nephrol. 2014; 25(6):1357-66. PMC: 4033365. DOI: 10.1681/ASN.2013040430. View

15.

Park S, Li C, Chen Y . Endoplasmic Reticulum Calcium Homeostasis in Kidney Disease: Pathogenesis and Therapeutic Targets. Am J Pathol. 2020; 191(2):256-265. PMC: 7863132. DOI: 10.1016/j.ajpath.2020.11.006. View

16.

Pan Y, Wan J, Liu Y, Yang Q, Liang W, Singhal P . sPLA2 IB induces human podocyte apoptosis via the M-type phospholipase A2 receptor. Sci Rep. 2014; 4:6660. PMC: 4205892. DOI: 10.1038/srep06660. View

17.

Mella A, Deambrosis I, Mingozzi S, Colla L, Burdese M, Giaretta F . Detection of urinary podocytes by flow cytometry in idiopathic membranous nephropathy. Sci Rep. 2020; 10(1):16362. PMC: 7530666. DOI: 10.1038/s41598-020-73335-2. View

18.

Schell C, Huber T . The Evolving Complexity of the Podocyte Cytoskeleton. J Am Soc Nephrol. 2017; 28(11):3166-3174. PMC: 5661293. DOI: 10.1681/ASN.2017020143. View

19.

Akilesh S, Huber T, Wu H, Wang G, Hartleben B, Kopp J . Podocytes use FcRn to clear IgG from the glomerular basement membrane. Proc Natl Acad Sci U S A. 2008; 105(3):967-72. PMC: 2242706. DOI: 10.1073/pnas.0711515105. View

20.

Pinton P, Giorgi C, Siviero R, Zecchini E, Rizzuto R . Calcium and apoptosis: ER-mitochondria Ca2+ transfer in the control of apoptosis. Oncogene. 2008; 27(50):6407-18. PMC: 2844952. DOI: 10.1038/onc.2008.308. View